For years, bevacizumab has been widely used in ophthalmology through repurposed oncology formulations. Lytenava (bevacizumab-vikg) changes that by becoming the first FDA-approved bevacizumab specifically developed for intravitreal use in patients with wet age-related macular degeneration.

By inhibiting VEGF, Lytenava reduces abnormal blood vessel growth and leakage that can lead to progressive vision loss. Having a formulation purpose-built for the eye provides clinicians with a treatment specifically designed for ophthalmic care.

Its arrival is expected to influence future retinal disease research and clinical trial design, making it an important molecule to monitor for comparator sourcing, exclusivity, and market adoption.